Cd19 chimeric antigen receptor t cell therapy for b cell malignancies

سال انتشار: 1396
نوع سند: مقاله کنفرانسی
زبان: انگلیسی
مشاهده: 443

نسخه کامل این مقاله ارائه نشده است و در دسترس نمی باشد

این مقاله در بخشهای موضوعی زیر دسته بندی شده است:

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:

شناسه ملی سند علمی:

NASTARANCANSER03_351

تاریخ نمایه سازی: 7 اسفند 1396

چکیده مقاله:

Refractory/relapsed B cell malignancies are one of the significant causes of cancer-associated mortality in the world. CD19 is expressed on majority of B cell malignancies just like normal B cells but not on other cell types. Developing new founded and effective molecular-targeted treatments have revolutionized cancer therapy. Last studies show that CD19 chimeric antigen receptor- directed T cellhas unprecedented outcomes in B-lineage malignancies.CAR T cells are produced by separating T cells from patient’s blood and reengineering the cells in order to express the CAR. CD19 CAR made up ofan extracellular single-chain variable fragment (SCFV) antibody to CD19 bind to T cell cytoplasmic signaling domains, activates T cell cytotoxicity which contact with CD19+ B cells causing permanentand particular elimination of B cells and persistent remission of malignancies. Therefor it’s an ideal target for treatment of B cell malignancies. Auto antigenic chimeric immuno receptor T cells have beendirected to eliminate B lymphocytes through the specificity of the B cell receptor (BCR). Altogether, the promising results are often accompanied with complications for example cytokine release syndrome(CRS), serious neurotoxicity and on-target off-tumor effect which more clinical applications of CAR T cell can be useful. Furthermore this kind of therapy increases the rate of relapse. Totally CD19 CAR Tcell therapy is encouraging therapy for cancer treatment and so far has acceptable outcomes in treatment of B cell malignancies. Up to 90% of B cell malignancies patients respond to this method ofcancer therapy but for being CAR T cell therapy as a global treatment, especially according to complication above it, should be utilized in form of allogeneic hematopoietic transplantation

کلیدواژه ها:

Blood Cancer ، Cell and Cancer ، Cancer Risks ، Cancer Treatment and Management ، Targeted Cancer Therapy

نویسندگان

Rana Kolahi Ahari

School Of Medicine, Mashhad Islamic Azad University, Mashhad, Iran

Mahnaz Sadeghi Pour Marvi

School Of Medicine, Mashhad Islamic Azad University, Mashhad, Iran

Mohammadreza Khojaste

School Of Medicine, Mashhad Islamic Azad University, Mashhad, Iran

Jalil Tavakol Afshari

Bu-Ali Research Center, Immunogenetic And Tissue Culture Department, Mashhad University Of Medical Sciences, Mashhad, Iran